| | |
Reuters 04:01 PM | November 11,2009
Patents protection for Roche’s Tamiflu in US and Europe has not allowed Cipla to sell its generic version in these two geographies, its chairman Y K Hamied said
|
|
Mark to Market | Mobis Philipose, Ravi Ananthanarayanan and Vatsala Kamat 01:00 AM | October 29,2009
Its turnover growth was affected by a 3.4% decline in formulation exports due to non-availability of a key raw material in its respiratory product segment
|
|
Archi Damania / CNBC-TV18 12:53 AM | October 29,2009
Cipla chairman and managing director Y.K. Hamied said a lot of the growth has been in the anti-AIDS drugs
|
|
C.H. Unnikrishnan 11:04 PM | October 28,2009
The US drug regulator earlier this year seized all inventories at Caraco’s Michigan plant after it failed to comply with manufacturing quality norms
|
|
Lawfully Yours | AZB and Partners 10:20 PM | October 11,2009
Bayer contended DCGI should not approve any application for a generic drug if the original has been patented
|
|
PTI 10:27 AM | September 25,2009
Company’s board of directors have approved the issuance of up to 2.56 crore equity shares at Rs263.75 per equity share, thus garnering Rs676 crore
|
|
Pooja Thakur / Bloomberg 11:35 PM | September 23,2009
The companies are tapping a revival in investors’ appetite for stocks as India’s benchmark Sensex heads for its best annual performance in 18 years after climbing 73% this year
|
|
Mark to Market | Manas Chakravarty, Mobis Philipose and Ravi Ananthanarayanan 10:42 PM | September 23,2009
India, where Cipla has a 5.4% share in the retail market, contributes to about 40% of its revenues
|
|
Reuters 06:30 PM | September 22,2009
CLSA, JPMorgan and Kotak Mahindra Capital Co are the arrangers for the deal
|
|
Reuters 12:13 PM | September 14,2009
Dr Reddy’s and local rivals such as Ranbaxy Laboratories Ltd and Cipla Ltd have thrived on booming global demand for generic drugs as nations around the world battle rising healthcare costs
|
|
Khushboo Narayan and C.H. Unnikrishnan 11:46 PM | September 11,2009
The department has charged Okasa with claiming I-T deduction worth crores of rupees on drugs that were actually manufactured by at least a dozen contract suppliers.
|
|
C.H. Unnikrishnan 11:56 PM | September 10,2009
Firm to take on rivals by launching versions of top-selling drugs, to address both chronic and infectious diseases
|
|
C.H. Unnikrishnan 05:40 AM | September 08,2009
The three provisions relate to pre-grant opposition, post-grant opposition, and section 3(d)
|
|
Radhieka Pandeya 12:37 AM | August 28,2009
The government’s move will allow people to buy Oseltamivir from designated chemists and other distribution channels if they have a prescription
|
|
CNBC-TV18 10:01 PM | August 27,2009
CNBC-TV18 meets the top gainers and losers and finds out what the players feel about Thursday’s markets
|
|